LIVN Stock Analysis: LivaNova | NASDAQ
Medical Devices | NASDAQ, USA | Market Cap: 4.533m USD | 12M Return: 76.9% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 61.1M
EPS Trend: 96.8%
Qual. Beats: 1
Rev. Trend: 99.6%
Qual. Beats: 15
Warnings
Tailwinds
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
LivaNova PLC (NASDAQ: LIVN) is a UK-incorporated medical technology company headquartered in London that designs, manufactures, and sells medical devices and therapies across two main segments: Cardiopulmonary (heart-lung machines, oxygenators, autotransfusion and perfusion tubing systems, cannulae) and Neuromodulation (the VNS Therapy System for drug-resistant epilepsy and difficult-to-treat depression, plus the aura6000 system in development for obstructive sleep apnea). The company markets its products in roughly seventeen countries, primarily in the United States, the United Kingdom, and Western Europe, and reaches hospitals and healthcare providers through a mix of direct sales representatives, agents, and independent distributors.
As a medical device manufacturer, LivaNova operates in a heavily regulated industry subject to FDA, CE mark, and other national approval requirements, which tend to create high barriers to entry and long product development cycles. The business model depends on hospital capital purchasing, procedure volumes, and third-party reimbursement, and segment diversification across cardiac surgery and neurostimulation helps offset cyclicality in any single clinical specialty.
- Cardiopulmonary segment revenue grows on heart-lung machine demand
- VNS Therapy adoption expands in drug-resistant epilepsy market
- aura6000 sleep apnea pipeline challenges Inspire Medical Systems
| Net Income: 107.1m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.06 > 0.02 and ΔFCF/TA 0.71 > 1.0 |
| NWC/Revenue: 17.56% < 20% (prev 33.68%; Δ -16.12% < -1%) |
| CFO/TA 0.10 > 3% & CFO 245.6m > Net Income 107.1m |
| Net Debt (-149.5m) to EBITDA (215.7m): -0.69 < 3 |
| Current Ratio: 1.33 > 1.5 & < 3 |
| Outstanding Shares: last quarter (55.9m) vs 12m ago 2.72% < -2% |
| Gross Margin: 67.57% > 18% (prev 69.02%; Δ -1.45% > 0.5%) |
| Asset Turnover: 56.49% > 50% (prev 49.84%; Δ 6.64% > 0%) |
| Interest Coverage Ratio: 3.37 > 6 (EBIT TTM 172.7m / Interest Expense TTM 51.2m) |
| A: 0.10 (Total Current Assets 1.01b - Total Current Liabilities 762.5m) / Total Assets 2.52b |
| B: -0.45 (Retained Earnings -1.12b / Total Assets 2.52b) |
| C: 0.07 (EBIT TTM 172.7m / Avg Total Assets 2.54b) |
| D: 0.93 (Book Value of Equity 1.21b / Total Liabilities 1.30b) |
| Altman-Z'' = 0.63 = B |
| DSRI: 0.88 (Receivables 229.3m/231.4m, Revenue 1.43b/1.28b) |
| GMI: 1.02 (GM 69.02% / 67.57%) |
| AQI: 1.04 (AQ_t 0.47 / AQ_t-1 0.45) |
| SGI: 1.12 (Revenue 1.43b / 1.28b) |
| TATA: -0.06 (NI 107.1m - CFO 245.6m) / TA 2.52b) |
| Beneish M = -3.00 (Cap -4..+1) = A |
As of July 11, 2026, the stock is trading at USD 82.56 with a total of 445,886 shares traded. Over the past week, the price has changed by -1.27%, over one month by +5.33%, over three months by +31.51% and over the past year by +76.90%.
Current recommended Stop Loss: 79.80 (which is 3.3% or 1.2 ATR below the current price).
LivaNova has received a consensus analysts rating of 4.09. Therefore, it is recommended to buy LIVN.
- StrongBuy: 4
- Buy: 4
- Hold: 3
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 81.5 | -1.3% |
P/E Trailing = 42.0969
P/E Forward = 19.7628
P/S = 3.162
P/B = 3.7917
P/EG = 0.9256
Revenue TTM = 1.43b USD
EBIT TTM = 172.7m USD
EBITDA TTM = 215.7m USD
Long Term Debt = 285.2m USD (from longTermDebt, last quarter)
Short Term Debt = 2.60m USD (from shortTermDebt, last quarter)
Debt = 390.2m USD (from shortLongTermDebtTotal, last quarter) + Leases 55.7m
Net Debt = -149.5m USD (calculated: Debt 390.2m - CCE 539.7m)
Enterprise Value = 4.38b USD (4.53b + Debt 390.2m - CCE 539.7m)
Interest Coverage Ratio = 3.37 (Ebit TTM 172.7m / Interest Expense TTM 51.2m)
EV/FCF = 27.21x (Enterprise Value 4.38b / FCF TTM 161.1m)
FCF Yield = 3.67% (FCF TTM 161.1m / Enterprise Value 4.38b)
FCF Margin = 11.24% (FCF TTM 161.1m / Revenue TTM 1.43b)
Net Margin = 7.47% (Net Income TTM 107.1m / Revenue TTM 1.43b)
Gross Margin = 67.57% ((Revenue TTM 1.43b - Cost of Revenue TTM 464.9m) / Revenue TTM)
Gross Margin QoQ = 67.59% (prev 66.45%)
Tobins Q-Ratio = 1.74 (Enterprise Value 4.38b / Total Assets 2.52b)
Interest Expense / Debt = 13.13% (Interest Expense 51.2m / Debt 390.2m)
Taxrate = 11.85% (14.4m / 121.5m)
NOPAT = 152.3m (EBIT 172.7m * (1 - 11.85%))
Current Ratio = 1.33 (Total Current Assets 1.01b / Total Current Liabilities 762.5m)
Debt / Equity = 0.32 (Debt 390.2m / totalStockholderEquity, last quarter 1.21b)
Debt / EBITDA = -0.69 (Net Debt -149.5m / EBITDA 215.7m)
Debt / FCF = -0.93 (Net Debt -149.5m / FCF TTM 161.1m)
Total Stockholder Equity = 1.17b (last 4 quarters mean from totalStockholderEquity)
RoA = 4.22% (Net Income 107.1m / Total Assets 2.52b)
RoE = 9.13% (Net Income TTM 107.1m / Total Stockholder Equity 1.17b)
RoCE = 11.85% (EBIT 172.7m / Capital Employed (Equity 1.17b + L.T.Debt 285.2m))
RoIC = 9.04% (NOPAT 152.3m / Invested Capital 1.68b)
WACC = 9.63% (E(4.53b)/V(4.92b) * Re(9.46%) + D(390.2m)/V(4.92b) * Rd(13.13%) * (1-Tc(0.12)))
Discount Rate = 9.46% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 55.56 | Cagr: 1.30%
[DCF] Terminal Value 72.55% ; FCFF base≈154.9m ; Y1≈169.2m ; Y5≈212.3m
[DCF] Fair Price = 51.10 (EV 2.66b - Net Debt -149.5m = Equity 2.81b / Shares 54.9m; r=9.63% [WACC]; 5y FCF grow 10.69% → 2.50% )
EPS Correlation: 96.80 | EPS CAGR: 15.18% | SUE: 1.04 | # QB: 1
Revenue Correlation: 99.58 | Revenue CAGR: 9.94% | SUE: 4.0 | # QB: 15
EPS current Quarter (2026-06-30): EPS=1.09 | Chg30d=+0.17% | Revisions=+38% | Analysts=10
EPS next Quarter (2026-09-30): EPS=1.08 | Chg30d=+0.27% | Revisions=-30% | Analysts=10
EPS current Year (2026-12-31): EPS=4.25 | Chg30d=+0.07% | Revisions=+73% | GrowthEPS=+9.0% | GrowthRev=+8.6%
EPS next Year (2027-12-31): EPS=4.62 | Chg30d=-0.26% | Revisions=+55% | GrowthEPS=+8.6% | GrowthRev=+7.0%
[Analyst] Revisions Ratio: +45% (up=21, down=7)